SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has reported record second-quarter revenue of $13.9 million, a 39.4% increase year over year. The company's first-half revenue reached $25.0 million, up 65.6% from the same period in 2025, underscoring accelerating demand for its SSi Mantra surgical robotic system.
The company's system installations rose 30.4% to 30 units during the quarter, bringing the total installed base to 224 SSi Mantra systems across 12 countries. Cumulative surgeries performed on the platform reached 12,272, demonstrating growing clinical adoption. Gross profit for the quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter, reflecting investments in scaling operations.
For the first half, gross profit increased 77.5% to $12.4 million, with improved margin compared to the prior year. These results signal that SS Innovations is successfully commercializing its robotic surgery platform, which competes in a market dominated by established players like Intuitive Surgical.
The company's telesurgery achievements are extending the clinical profile of SSi Mantra, while system installations remain the primary commercial growth driver. Telesurgery capabilities allow surgeons to operate remotely, potentially expanding access to robotic surgery in underserved regions and enhancing the platform's value proposition.
Looking ahead, regulatory milestones could serve as important catalysts. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open access to the large U.S. and European markets, which are currently dominated by competitors. The company's progress in these areas will be closely watched by investors and healthcare providers alike.
The latest news and updates relating to SSII are available in the company's newsroom at https://nnw.fm/SSII.
